Perceptions and Behaviors of Patients with Inflammatory Bowel Disease during the COVID-19 Crisis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: This study aimed to investigate the perceptions and behaviors of patients with inflammatory bowel disease (IBD) during the early coronavirus disease 2019 (COVID-19) pandemic in the major epidemic area in Korea. Methods: Between April and May 2020, a cross-sectional survey was performed at two tertiary hospitals in Daegu, South Korea, on patients’ experiences, coping strategies and perceptions. Results: Most of the 544 patients participating in the survey strictly adhered to personal protection guidance against COVID-19. In the early COVID-19 crisis, many patients canceled or postponed hospital visits (57.5%) and rescheduled biologics administrations (26.4%). Although 13.6% utilized telemedicine, the frequency of individuals leaving their homes remained unchanged. Although 50.4% were concerned about their susceptibility to COVID-19, 72.2% adhered to their treatment for IBD. In patients taking biologics or Janus kinase inhibitors, 86.8% disagreed that they should discontinue their medication as a preventative measure against COVID- 19, but 21.9% actually discontinued their medications. Of those with discordance between the perception of IBD drug adherence and active behaviors, 5.4% of all and 39.4% of biologics or Janus kinase inhibitors withheld drugs specifically due to fear of COVID-19. Only 7% of all patients discussed drug safety with their physicians. The level of concern for COVID-19 depended on the type of drug used. Conclusions: Patients with IBD showed concerns about the increased risk of COVID-19 due to IBD or their medications, and a considerable number of patients withheld their medications without consulting medical staff. Enhanced active communications with patients with IBD and appropriate health-related education should be provided.
Abstract
Background/Aims: This study aimed to investigate the perceptions and behaviors of patients with inflammatory bowel disease (IBD) during the early coronavirus disease 2019 (COVID-19) pandemic in the major epidemic area in Korea. Methods: Between April and May 2020, a cross-sectional survey was performed at two tertiary hospitals in Daegu, South Korea, on patients’ experiences, coping strategies and perceptions. Results: Most of the 544 patients participating in the survey strictly adhered to personal protection guidance against COVID-19. In the early COVID-19 crisis, many patients canceled or postponed hospital visits (57.5%) and rescheduled biologics administrations (26.4%). Although 13.6% utilized telemedicine, the frequency of individuals leaving their homes remained unchanged. Although 50.4% were concerned about their susceptibility to COVID-19, 72.2% adhered to their treatment for IBD. In patients taking biologics or Janus kinase inhibitors, 86.8% disagreed that they should discontinue their medication as a preventative measure against COVID- 19, but 21.9% actually discontinued their medications. Of those with discordance between the perception of IBD drug adherence and active behaviors, 5.4% of all and 39.4% of biologics or Janus kinase inhibitors withheld drugs specifically due to fear of COVID-19. Only 7% of all patients discussed drug safety with their physicians. The level of concern for COVID-19 depended on the type of drug used. Conclusions: Patients with IBD showed concerns about the increased risk of COVID-19 due to IBD or their medications, and a considerable number of patients withheld their medications without consulting medical staff. Enhanced active communications with patients with IBD and appropriate health-related education should be provided.
참고문헌 (27)
- Lee JY, "Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea", Int J Infect Dis, 98, pp.462~466 (2020)
- Han Sol Chung, "Revised Triage and Surveillance Protocols for Temporary Emergency Department Closures in Tertiary Hospitals as a Response to COVID-19 Crisis in Daegu Metropolitan City", Journal of Korean Medical Science, 35(19), pp.1~10 (2020), 대한의학회[DOI]
- Satsangi J, "The Montreal classification of inflammatory bowel disease : controversies, consensus, and implications", Gut, 55, pp.749~753 (2006)
- Goodsall TM, "Understanding attitudes, concerns, and health behaviors of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic", J Gastroenterol Hepatol, 36, pp.1550~1555 (2021)
- Grunert PC, "Inflammatory bowel disease in the COVID-19 pandemic : the patients’ perspective", J Crohns Colitis, 14, pp.1702~1708 (2020)
- D’Amico F, "Views of patients with inflammatory bowel disease on the COVID-19 pandemic : a global survey", Lancet Gastroenterol Hepatol, 5, pp.631~632 (2020)
- Tinsley A, "Increased risk of influenza and influenza-related complications among 140, 480patients with inflammatory bowel disease", Inflamm Bowel Dis, 25, pp.369~376 (2019)
- Rubin DT, "AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic : expert commentary", Gastroenterology, 159, pp.350~357 (2020)
- Taxonera C, "2019 novel coronavirus disease(COVID-19)in patients with inflammatory bowel diseases", Aliment Pharmacol Ther, 52, pp.276~283 (2020)
- Singh S, "Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the United States : a multicenter research network study", Gastroenterology, 159, pp.1575~1578 (2020)
- Magro F, "Inflammatory bowel disease management during the COVID-19 outbreak : the ten do’s and don’ts from the ECCO-COVID Taskforce", J Crohns Colitis, 14(Supplement_3), pp.S798~S806 (2020)
- Hyung-Ju Kim, "The Delay in Confirming COVID-19 Cases Linked to a Religious Group in Korea", 예방의학회지, 53(3), pp.164~167 (2020), 대한예방의학회[DOI]
- Anupam K. Singh, "Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis", Intestinal research, 20(1), pp.134~143 (2022), 대한장연구학회[DOI]
- Trindade IA, "COVID-19 pandemic’s effects on disease and psychological outcomes of people with inflammatory bowel disease in Portugal : a preliminary research", Inflamm Bowel Dis, 27, pp.1224~1229 (2021)
- Singh S, "Comparative risk of serious infections with biologic and", or immunosuppressive therapy in patients with inflammatory bowel diseases : a systematic review and meta-analysis, 2020, pp.18, 69~81
- Khan N, "Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases : a nationwide cohort study", Clin Gastroenterol Hepatol, 16, pp.1919~1927 (2018)
- Wisniewski A, "Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines", United European Gastroenterol J, 8, pp.303~313 (2019)
- Bezzio C, "Outcomes of COVID-19 in 79 patients with IBD in Italy : an IG-IBD study", Gut, 69, pp.1213~1217 (2020)
- Kennedy NA, "British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic", Gut, 69, pp.984~990 (2020)
- 김경옥, "Management of inflammatory bowel disease in the COVID-19 era", Intestinal research, 20(1), pp.3~10 (2022), 대한장연구학회[DOI]
- D’Amico F, "Inflammatory bowel disease management during the coronavirus-19 outbreak : a survey from the European Crohn’s and Colitis Organization", Gastroenterology, 159, pp.14~19 (2020)
- Ungaro RC, "Effect of IBD medications on COVID-19 outcomes : results from an international registry", Gut, 70, pp.725~732 (2021)
- Spagnuolo R, "COVID-19 and inflammatory bowel disease: patient knowledge and perceptions in a single center survey", Medicina(Kaunas), 56, pp.407~ (2020)
- "Advice for the public mythbusters, FACT: Vaccines against pneumonia DO NOT protect against the COVID-19 virus" (2020)[URL]
- Ahmed W, "Social media in inflammatory bowel disease : the patient and physician perspective", Curr Opin Gastroenterol, 37, pp.328~335 (2021)
- Harris RJ, "Life in lockdown : experiences of patients with IBD during COVID-19", BMJ Open Gastroenterol, 7, pp.e000541~ (2020)
- Danese S, "The day after COVID-19 in IBD : how to go back to ‘normal’", Nat Rev Gastroenterol Hepatol, 17, pp.441~443 (2020)